Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 4/2013

01-08-2013 | Adis Drug Clinical Q&A

Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares

Author: Katherine A. Lyseng-Williamson

Published in: BioDrugs | Issue 4/2013

Login to get access

Abstract

Canakinumab (Ilaris®), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a targeted population of patients in whom treatment options are limited. Relative to on-demand treatment with intramuscular triamcinolone acetonide 40 mg, on-demand treatment with subcutaneous canakinumab 150 mg significantly relieved the pain and inflammation of a new gout flare, and reduced the risk of new flares in patients with acute gouty arthritis flares in whom standard treatment with non-steroidal anti-inflammatories and/or colchicine was inappropriate. Canakinumab has an acceptable tolerability profile in this difficult-to-treat population. The increased risk of infections and neutropenia associated with canakinumab treatment can be minimized by following the recommended precautions.

Literature
  1. Schlesinger N. Difficult-to-treat gouty arthritis: a disease warranting better management. Drugs. 2011;71(11):1413–9.PubMedView Article
  2. Kingsbury SR, Conaghan PG, McDermott MF. The role of the NLRP3 inflammasome in gout. J Inflamm Res. 2011;4:39–49.PubMed
  3. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J Clin Rheumatol. 2013;19(1):19–29.PubMed
  4. Stamp LK, Jordan S. The challenges of gout management in the elderly. Drug Aging. 2011;28(8):591–603.View Article
  5. Hamburger M, Baraf HS, Adamson TC 3rd, et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011;123(6 Suppl 1):3–36.PubMedView Article
  6. Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155–65.PubMedView Article
  7. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431–46.View Article
  8. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–24.PubMedView Article
  9. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447–61.View Article
  10. Ilaris (canakinumab) 150 mg powder for solution for injection: summary of product characteristics. London: European Medicines Agency; 2013.
  11. Curran MP. Canakinumab in patients with cryopyrin-associated periodic syndromes. Biodrugs. 2012;26(1):53–9.PubMedView Article
  12. Church LD, McDermott MF. Canakinumab, a fully human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009;11(1):81–9.PubMed
  13. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1–18.PubMedView Article
  14. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R6.View Article
  15. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012;71(11):1839–48.PubMedView Article
  16. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62(10):3064–76.PubMedView Article
  17. Schlesinger N, De Meulemeester M, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther. 2011;13(2):R53.PubMedView Article
  18. Doherty M, Bardin T, Pascual E. International survey on the diagnosis and management of gout. Ann Rheum Dis. 2007;66(12):1685–6.PubMedView Article
  19. Doherty M, Jansen TL, Nuki G, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71(11):1765–70.PubMedView Article
  20. Edwards NL. Quality of care in patients with gout: why is management suboptimal and what can be done about it? Curr Rheumatol Rep. 2011;13(2):154–9.PubMedView Article
  21. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011;70(7):1264–71.PubMedView Article
Metadata
Title
Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares
Author
Katherine A. Lyseng-Williamson
Publication date
01-08-2013
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 4/2013
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-013-0037-2

Other articles of this Issue 4/2013

BioDrugs 4/2013 Go to the issue

Adis Drug Clinical Q&A

Asparaginase Erwinia chrysanthemi (Erwinaze®): A Guide to Its Use in Acute Lymphoblastic Leukemia in the USA

Leading Article

Therapeutic Potential of Regulatory T cells in Autoimmune Disorders

Adis Drug Evaluation

Bevacizumab Combination Therapy: A Review of its Use in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Review Article

TNF Inhibition for Ophthalmic Indications: Current Status and Outlook

Review Article

Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents

Review Article

RNA Interference in the Treatment of Colon Cancer